首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到19条相似文献,搜索用时 62 毫秒
1.
紫外分光光度法快速测定恩诺沙星注射液的含量   总被引:2,自引:0,他引:2  
应用三个实验室3台不同型号的紫外分光光度计在271nm波长处对恩诺沙星的吸收系数进行测定,经统计分析,确定恩诺沙星在271nm波长的吸收系数(E1cm)为1008,RSD为0.37%,含量测定结果与《中国兽药典》对照品方法测得结果基本一致,方法经济、简单、快速,结果令人满意。1%  相似文献   

2.
建立了复方恩诺沙星可溶性粉中恩诺沙星和盐酸多西环素含量的检测方法.采用双波长紫外分光光度法,直接测定两组分的含量.结果显示可同时测出复方恩诺沙星可溶性粉中恩诺沙星和盐酸多西环素的各自含量,且吸收度与各自的浓度成良好线性关系.恩诺沙星平均回收率为100.1%,RSD为0.04%(n=5).盐酸多西环素平均回收率为100.2%,RSD为0.14%(n=5).本方法简便、快速、可靠,可用于复方恩诺沙星可溶性粉的含量测定.  相似文献   

3.
(目的)研究检测恩诺沙星的胶体金核酸适配体比色法,(方法)将恩诺沙星核酸适配体与胶体金结合后形成胶体金适配体复合物,然后加入恩诺沙星靶标分子,由于核酸适配体与靶标的高效特异性结合,核酸适配体与胶体金解离.最后加入NaCl后,胶体金由红变兰.(结果)胶体金比色检测体系中,NaCl的最佳浓度为1M,核酸适配体的最佳浓度为2μM.对恩诺沙星的比色检测限为15ng/mL.(结论)基于胶体金和核酸适配体的比色法可用于恩诺沙星的快速筛选.  相似文献   

4.
恩诺沙星是德国Bayer公司率先开发的氟喹诺酮类兽医专用的合成抗菌药,通常是以氟喹啉酸和N-乙基哌嗪为起始物质,经过缩合,再经成盐至恩诺沙星。在合成过程中,产生了一些杂质。杂质可以是溶剂、试剂、起始物质、无机物、反应的副产物、反应的中间体和降解产物。后三者在结构上与药物成分有关,常常被称为相关物质,通常用HPLC方法来测定。  相似文献   

5.
36只黄羽肉鸡,随机均分为3组,每组12只,分别进行恩诺沙星、恩诺沙星钠和盐酸恩诺沙星的药动学试验,高致液相色谱法测定鸡只血浆中恩诺沙星浓度,MCPKP程序处理药-时数据。恩诺沙星、恩诺沙星钠和盐酸恩诺沙星溶液经内服给药后在鸡体内最佳药动学模型为一级吸收一室模型,峰浓度高(峰浓度分别为2.39、2.04和2.37μg/mL),吸收快(吸收半衰期t1/2Ka分别为1.15h、0.76h和1.55h),消除缓慢(消除半衰期t1/2K分别为8.39h、12.19h和10.95h)。以恩诺沙星做对照,恩诺沙星钠和盐酸恩诺沙星内服给药后吸收完全,其相对生物利用度高,分别为103.2%和126.8%。恩诺沙星钠和盐酸恩诺沙星内服给药后主要药动学参数与恩诺沙星给药后的药动学参数相比均无显著性差异.  相似文献   

6.
采用HPLC法测定恩诺沙星可溶性粉的含量,色谱柱选用Waters Symmetry C18柱(4.6×150mm,5μm),流动相为0.025 mol/L磷酸(用三乙胺调节pH至3.0)—乙腈(83∶17),检测波长为278 nm,柱温25℃,流速1.0 mL/min.结果表明恩诺沙星在20~80 μg/mL的范围内,呈现良好的线性关系,平均回收率为99.3%.通过试验确定本法的检测限为15 μg/mL,定量限为50 μg/mL,且具有良好的专属性和耐用性.运用本法对来自四个不同厂家的恩诺沙星可溶性粉进行含量测定,并与紫外分光光度法测定结果比较,说明HPLC法能准确测定恩诺沙星可溶性粉的含量.  相似文献   

7.
贾涛 《饲料研究》2012,(10):71-74
恩诺沙星、环丙沙星和沙拉沙星属于化学合成抗菌素类药物,在动物的饲料中添加会减少动物感染肠道类疾病的概率,但是恩诺沙星、环丙沙星和沙拉沙星这类药物却会残留在动物的肌肉组织中,人食用后会给人体健康带来不利影响,对生长发育中的儿童影响尤其不利,细菌耐药和不良反应也相继发生,主要有过敏、溢血和肾衰等不良反应.此外还有可能诱发精神病及癫痫患者发病的风险,增加胎儿畸形的风险.以超高效液相色谱-荧光法(UPLC)检测饲料中的恩诺沙星、环丙沙星和沙拉沙星类违禁药物进行探讨,试样用磷酸盐缓冲溶液提取,C18萃取柱净化,流动相洗脱后,用超高效液相色谱-荧光检测器测定,激发波长280 nm,发射波长450 nm处测定其吸光度,同条件下测定恩诺沙星、环丙沙星和沙拉沙星药物标准品相对应的峰面积响应值,恩诺沙星、环丙沙星和沙拉沙星含量与吸光度值在一定质量浓度范围内成正比,试样与标准品比较定量.经试验,此方法具有操作简单、回收率稳定和检测时间短等优点;标准品峰面积响应值稳定,此方法在环丙沙星、恩诺沙星和沙拉沙星质量浓度为0.1~0.5 μg/mL时,能够达到较好线性系数,符合检测时的相关要求;恩诺沙星相关系数r≥0.999 96,环丙沙星相关系数r≥0.999 87,沙拉沙星相关系数r≥0.999 82.恩诺沙星平均回收率为83.5 %~96.5%,批内变异系数≤4.2%,批间变异系数≤7.5%;环丙沙星的平均回收率为74.9 %~95.5%,批内变异系数≤5.1%,批间变异系数≤7.7%;沙拉沙星平均回收率为80.1%~95.0%,批内变异系数≤4.5%,批间变异系数≤6.5%.  相似文献   

8.
拉曼和红外光谱法验证恩诺沙星固体分散体   总被引:2,自引:2,他引:0  
用拉曼光谱法鉴别恩诺沙星固体分散体,以期获得一种新的简单易行的固体分散体的验证方法。采用熔融法制备恩诺沙星固体分散体,用显微共焦拉曼光谱仪和傅里叶变换红外光谱仪分别采集恩诺沙星粉末、PEG 6000、恩诺沙星∶PEG 6000(1∶6)的物理混合物以及恩诺沙星固体分散体的拉曼光谱和红外光谱并进行对比分析。恩诺沙星与PEG 6000之间存在氢键效应,恩诺沙星高度分散在PEG 6000中。结果说明拉曼光谱法快速、直接、对样品无损伤,是一种理想的验证固体分散体的方法。  相似文献   

9.
本文报告了用三台不同型号的紫外分光光度计在271nm波长处对恩诺沙星的吸收系数进行测定的结果,经统计分析确定,E_(1cm)~(1%)为995,RSD为0.47%,并用E_(1cm)~(1%)测定了恩诺沙星三种剂型的含量,经和对照品法进行对比,取得了满意结果。  相似文献   

10.
强力恩诺沙星可溶性粉中有效成分含量的检测   总被引:1,自引:0,他引:1  
采用双波长等吸收分光光度法同时测定强力恩诺沙星可溶性粉中恩诺沙星和硫酸小檗碱的含量。线性范围恩诺沙星2~10(μg/m1),γ=0.99999;硫酸小檗碱8~16(μg/m1),γ=0.9995;平均回收率为:恩诺沙星99.4%(n=5),RSD为0.21%;硫酸小檗碱99.5%(n=5),RSD为0.26%。  相似文献   

11.
采用湿法制粒、流化床包衣制备肠溶释放微粒,正交法进行工艺参数的筛选,通过溶出度试验对其释放特性进行考察,筛选出最佳生产工艺.在此优化工艺条件下制得的微粒体外释放特性良好,在人工胃液中几乎不溶,而在人工肠液中释放达到70%以上.本品处方合理,制备工艺简单,达到了肠溶释放的目的,为恩诺沙星制剂的优化提供了依据.  相似文献   

12.
恩诺沙星在鹅体内的药代动力学研究   总被引:1,自引:0,他引:1  
本文对恩诺沙星在鹅体内的药动学特征进行了研究,36只鹅随机分为2组,A组静脉注射恩诺沙星溶液;B组口服恩诺沙星溶液,给药剂量均为10mg/kg体重。数据采用DAS2.0进行分析。试验结果显示,静脉注射组多项药动学参数与口服组相比存在较显著差异,静脉注射组AUC约为口服组的1.3倍,在其体内清除率仅为口服组的3/5,但在体内消除却较快,平均驻留时间仅为口服组的7/10,结合恩诺沙星对常见敏感菌的MIC参数考虑,可以认为,口服10mg/kg剂量可以满足临床养殖中抗敏感细菌感染的要求。  相似文献   

13.
The pharmacokinetics of enrofloxacin (EFL) and its active metabolite ciprofloxacin (CIP) was investigated in 7-8 month old turkeys (6 birds per sex). EFL was administered intravenously (i.v.) and orally (p.o.) at a dose 10 mg kg(-1) body weight. Blood was taken prior to and at 0.17, 0.33, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 h following drug administration. The concentrations of EFL and CIP in blood serum were determined by high-performance liquid chromatography (HPLC). Serum concentrations versus time were analysed by a noncompartmental analysis. The elimination half-live and the mean residence time of EFL after i.v. injection for the serum were after oral administration 6.64+/-0.90 h, 8.96+/-1.18 h and 6.92+/-0.97 h, 11.91+/-1.87 h, respectively. After single p.o. administration, EFL was absorbed slowly (MAT=2.76+/-0.48 h) with time to reach maximum serum concentrations of 6.33+/-2.54 h. Maximum serum concentrations was 1.23+/-0.30 microg mL(-1). Oral bioavailability for for EFL after oral administration was found to be 69.20+/-1.49%. The ratios C(max)/MIC and AUC(0 --> 24)/MIC were respectively from 161.23+/-5.9 h to 12.90+/-0.5 h for the pharmacodynamic predictor C(max)/MIC, and from 2153.44+/-66.6 h to 137.82+/-4.27 h for AUC(0 --> 24)/MIC, for the different clinically significant microorganisms, whose values for MIC varies from 0.008 microg L(-1) to 0.125 microg mL(-1).  相似文献   

14.
为获得恩诺沙星特征拉曼峰的归属信息,建立快速、灵敏的定性分析方法,采用共焦显微激光拉曼技术,测得了恩诺沙星的拉曼散射图谱,并对其各个特征峰进行指认归属.实验表明,恩诺沙星的O-C-O在1 394.9 cm-1处的对称伸缩振动十分强烈.环丙基的CH2在3 005cm-1,3 069.4 cm-1处的对称与非对称伸缩振动非...  相似文献   

15.
用高效液相色谱法同时分离测定赛鸽用复方恩诺沙星胶囊中恩诺沙星和甲氧苄啶的含量.采用Nova-PakC18柱(150 mm×3.9 mm,4 μm),以乙腈-磷酸溶液(0.025 mol/L的磷酸溶液用三乙胺调节至pH 3.5,摇匀,经0.45 μm滤膜滤过)(15∶ 85,V/V)为流动相,流速为1.0 mL/min,检测波长为254 nm,柱温25 ℃.在此色谱条件下,恩诺沙星和甲氧苄啶的分离良好,它们的峰面积响应与浓度分别在25.1~150.4 μg/mL和12.6~75.5 μg/mL范围内呈良好线性关系(r>0.999);按外标法进行测定,以峰面积计算,恩诺沙星和甲氧苄啶的平均回收率分别为(99.5±0.49)%和(99.6±0.72)%,n=9;RSD分别为0.49%和0.72%.该法操作简便易行,系统适用性良好,适用于赛鸽用复方恩诺沙星胶囊中恩诺沙星和甲氧苄啶含量的测定.  相似文献   

16.
Rung, K., Riond, J.-L. & Wanner, M. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. J. vet
Four dogs were given 5 mg/kg body weight enrofloxacin intravenously (i.v.) and orally (p.o.) in a cross-over study. Plasma concentrations of the active ingredient enrofloxacin and its main metabolite ciprofloxacin were determined by a reversed phase liquid chromatographic method. Pharmacokinetic parameters of both substances were calculated by use of statistical moments and were compared to those of enrofloxacin described in the veterinary literature. Mean enrofloxacin t ½λZ was 2.4 h, mean Cls was 27.1 ml/min-kg, and mean Vss was 7.0 1/kg. After i.v. and p.o. administration, concentrations of ciprofloxacin exceeding minimal inhibitory concentrations of several microorganisms were reached (Cmax= 0.2 ng/ml, max = 2.2 h after intravenous administration; Cmax= 0.2 (ig/ml, t max= 3.6 h after oral administration). A considerable part of the antimicrobial activity is due to ciprofloxacin, the main metabolite of enrofloxacin.  相似文献   

17.
OBJECTIVE: To determine the pharmacokinetics of enrofloxacin in neonatal kittens and compare the pharmacokinetics of enrofloxacin in young and adult cats. ANIMALS: 7 adult cats and 111 kittens (2 to 8 weeks old). PROCEDURE: A single dose of 5 mg of enrofloxacin/kg was administered to adults (i.v.) and kittens (i.v., s.c., or p.o.). Plasma concentrations of enrofloxacin and its active metabolite, ciprofloxacin, were determined. RESULTS: The half-life of enrofloxacin administered i.v. in 2-, 6-, and 8-week-old kittens was significantly shorter and its elimination rate significantly greater than that detected in adults. The apparent volumes of distribution were lower at 2 to 4 weeks and greater at 6 to 8 weeks. This resulted in lower peak plasma concentration (Cmax) at 6 to 8 weeks; however, initial plasma concentration was within the therapeutic range after i.v. administration at all ages. Compared with i.v. administration, s.c. injection of enrofloxacin in 2-week-old kittens resulted in similar Cmax, half-life, clearance, and area under the curve values. Enrofloxacin administered via s.c. injection was well absorbed in 6- and 8-week-old kittens, but greater clearance and apparent volume of distribution resulted in lower plasma concentrations. Oral administration of enrofloxacin resulted in poor bioavailability. CONCLUSIONS AND CLINICAL RELEVANCE: In neonatal kittens, i.v. and s.c. administration of enrofloxacin provided an effective route of administration. Oral administration of enrofloxacin in kittens did not result in therapeutic drug concentrations. Doses may need to be increased to achieve therapeutic drug concentrations in 6- to 8-week-old kittens.  相似文献   

18.
19.
1. The pharmacokinetics and bioavailability of enrofloxacin in chickens were investigated following intravenous, intramuscular, subuctaneous and oral administration of 10 mg/kg body weight. A rapid distribution phase was followed by a slower elimination phase.

2. The apparent volume of distribution was 2.2 1/kg. Absorption half lives were 0.37, 0.36 and 0.92 h; elimination half lives were 4.06, 4.48 and 4.29 h and bioavailabilities were 87.5%, 80.8% and 59.6% after intramuscular, subcutaneous and oral administration, respectively. The drug completely disappeared from all tissues after 3 days following oral administration.

3. Based on the bioavailability and disposition kinetics of enrofloxacin, administration of one dose per day should both be practical and adequate to maintain plasma enrofloxacin concentrations within the pharmacologically active but lower than tolerance limit.  相似文献   


设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号